This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Varubi

Tesaro, Inc.

Drug Names(s): SCH 619734

Description: Rolapitant is a neurokinin-1 (NK-1) receptor antagonist.

Deal Structure: Rolapitant was originally developed by Schering-Plough.

Merck and Schering-Plough
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company. The acquisition was completed in November 2009.

Schering-Plough and OPKO
In October 2009, OPKO Health announced that it has entered into a definitive agreement with Schering-Plough to acquire assets relating to Schering's neurokinin-1 receptor antagonist program. The transaction was completed in November 2009.

Tesaro and OPKO
In December 2010, TESARO and OPKO signed a definitive agreement...See full deal structure in Biomedtracker

Partners: Opko Health Jiangsu Hengrui Medicine Co., Ltd.


Varubi News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug